JOIN OUR EUROPE 2018 STRATEGY MEETING
26th September, 2018 | Radisson Blu, Zurich Airport, Switzerland
OUR UNIQUE FORMAT
The Cell and Gene Therapy Roundtable Discussions Strategy Meeting is free to attend for qualified end-users.These include Senior Executives of Cell and Gene Therapy (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities
Thought leaders who will benefit from attending include Chief Executive Officer, Chief Scientific Officer, SVPs, EVPs, VPs, Executive Director, Director and Global Head responsible for:
– Cell Therapy, Cell Engineering, Biotherapeutics, Regenerative Medicine, Immune Deficiencies, CAR-T, Cellular Immunotherapy, Supply Chain, and Manufacturing.
Michael ZaiacVP, Head of Medical Affairs Haematology/Oncology EMEA
Margit JeschkeGlobal Head Analytical Development Cell and Gene Therapy
Rohit BattaSenior Medical Director - Gene Therapy Clinical Development
WHAT TO EXPECT
Interactive Roundtable Discussions
Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.
Director level one-to-one meetings
We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.
Tailor-fit and Personalized Agenda
Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.
Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.
Thank you for reaching Proventa International
CELL & GENE THERAPY
***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.
Our unique strategy meeting platform ensures that delegates can network with peers and benchmark their challenges whilst meeting a select number of supplier organizations that are currently at the forefront of innovation. This in turns helps them to save time and money associated in sourcing the best suppliers to procure solutions in an environment, which is 100% conducive to doing business.
If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!
WHAT PEOPLE SAY
Clinical Trial Supply Chain Strategy Meeting US East Coast 2016,
Pharma Supply Chain EU 2016 , Return on Investment attained at the meeting and why they are coming back
Chief Information Officer
Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative
Ivan John Clement
Data Scientist - R&D
Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.
Manager Quality Assurance
The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.
Founder & President
The kind of interaction is very interactive
Director & Professor
Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.
Images coming soon
Rondellstrasse, 8058 Kloten, Switzerland
+41 44 800 40 40
OUR MEDIA PARTNERS
VP, Head of Medical Affairs Haematology/Oncology EMEA, Celgene
Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992.
Since joining the pharmaceutical Industry in 1994 he covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large programmes for small molecules and monoclonal antibodies and the day-to-day management of medical affairs at country, regional and global level. He has published on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine.
Vice President, GMA Solid Tumors, Immuno-Oncology and Early Assets, Celgene
Vice President, Cancer Immunotherapy and Reprogramming Biology, Fate Therapeutics
Bob Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA and his M.B.A. from Pepperdine University.
Executive Vice President, Technical Operations, Bellicum Pharmaceuticals
Vice President - Vaccine Technology and Engineering, Takeda
Dr. Carrier is the Vice President of Vaccine Technology and Engineering at Takeda Vaccines, where his responsibilities include technical operations, lifecycle management, and engineering for commercial vaccine manufacturing. Prior to Takeda, Dr. Carrier held various positions at Biologics Consulting Group, Life Technologies and Merck and Co. Dr. Carrier was an adjunct faculty at University of Maryland and has taught as guest speaker in numerous courses on biologics manufacturing. Dr. Carrier has spent much of his career focusing on modular design and standardization in biologics manufacturing, having published and presented on the topic for over 15 years. Dr. Carrier holds an MBA from the University of Virginia and a PhD from the University of California, Berkeley.